A maker of surgical tools for treating atrial fibrillation, an irregular heartbeat, this Ohio company's devices include the AtriClip, a clamp that seals a small heart pouch to cut stroke risk, plus ablation systems and cryo probes that numb nerves to ease post-surgery pain. Founded in 2000 by engineer Michael Hooven, the company grew out of his drive to fill a gap in treating serious heart-rhythm problems. Its name blends "atria"—the heart's upper chambers where the condition starts—with "cure."
AtriCure shareholders approve 2023 Stock Incentive Plan amendment increasing shares to 6,000,000
All nine director nominees were elected to one-year terms expiring at the 2027 Annual Meeting.
Show detailsHide details
At the May 18, 2026 Annual Meeting, shareholders approved amending the 2023 Stock Incentive Plan to increase available shares from 4,500,000 to 6,000,000.
Shareholders ratified Deloitte & Touche LLP as independent auditor for fiscal year 2026.
Shareholders approved a 750,000 share increase under the 2018 Employee Stock Purchase Plan.
Advisory vote on named executive officer compensation was approved.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
AtriCure reports Q4 2025 revenue of $140.5M, up 13.1% year over year
Fourth quarter 2025 worldwide revenue was $140.5 million, a 13.1% increase year over year (12.1% on a constant currency basis).
Show detailsHide details
Fourth quarter 2025 net income was $1.8 million, with positive adjusted EBITDA of $19.9 million.
Full year 2025 worldwide revenue was $534.5 million, up 14.9% year over year, with a net loss of $11.4 million and positive adjusted EBITDA of $61.8 million.
Management projects full year 2026 revenue of approximately $600 million to $610 million, reflecting growth of approximately 12% to 14% over 2025.
Full year 2026 adjusted EBITDA is projected at approximately $80 million to $82 million, with positive net income and adjusted EPS of $0.09 to $0.15.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
AtriCure amends credit facility and reports preliminary Q4/full-year 2025 revenue and 2026 guidance
AtriCure entered a First Amendment to its JPMorgan credit agreement on Jan 9, 2026, extending the term by three years, reducing interest rates, and removing the minimum utilization covenant.
Show detailsHide details
The ABL facility provides up to $125 million, expandable to $165 million, secured by borrower assets and guaranteed by material domestic subsidiaries.
Preliminary Q4 2025 revenue is expected to be $140.5 million, up ~13% year-over-year (12% constant currency), with U.S. revenue of $114.3 million and international revenue of $26.2 million.
Preliminary full-year 2025 revenue is expected to be $534.5 million, up ~15% (14% constant currency), with adjusted EBITDA of $57-59 million and adjusted loss per share of $0.18-0.21.
For 2026, management projects revenue of $600-610 million (12-14% growth), adjusted EBITDA of $80-82 million, and anticipates full-year net income and continued positive cash flow.
The company ended 2025 with approximately $167 million in cash and investments.
1.01 Entry into a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits
Earnings8-K
AtriCure reports Q3 2025 revenue of $134.3M, up 15.8% year over year, and raises 2025 outlook
Net loss narrowed to $0.3 million from $7.9 million in Q3 2024; basic and diluted net loss per share was $0.01 versus $0.17.
Show detailsHide details
Worldwide revenue for Q3 2025 was $134.3 million, a 15.8% increase year over year (15.1% on a constant currency basis).
Adjusted EBITDA was $17.8 million, up $9.9 million from Q3 2024.
U.S. revenue grew 14.5% to $109.3 million; international revenue grew 22.0% to $25.0 million.
Full-year 2025 revenue guidance raised to approximately $532-$534 million, with adjusted EBITDA of $55-$57 million.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
AtriCure shareholders approve 2023 Stock Incentive Plan amendment increasing shares to 4.5 million
All nine director nominees were elected to one-year terms expiring at the 2026 Annual Meeting.
Show detailsHide details
At the May 19, 2025 Annual Meeting, shareholders approved an amendment to the 2023 Stock Incentive Plan, increasing available shares from 2,800,000 to 4,500,000.
Shareholders ratified Deloitte & Touche LLP as independent auditor for fiscal year 2025.
Advisory say-on-pay vote passed, and the Board decided to hold such votes annually.
The amendment to the stock plan was approved with 39,801,035 votes for and 1,299,938 against.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits